N/A N=2,600 Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Post-ERCP Pancreatitis — 47; 100 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=506 Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
Pancreatitis
Primary: Post ERCP Pancreatitis is the Primary Outcome. — 26; 20 participants — p=.45
N/A N=73 A Trial of Aprepitant For Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis
Pancreatitis
Primary: Number of Post-ERCP Pancreatitis Cases in Participants Who Are Administered Aprepitant and Placebo Prior to ERCP and One Day After ERCP:Assess the Total Number of…
Phase 3 N=192 Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: The Number of Participants With Acute Pancreatitis After ERCP as Assessed by Worsening Abdominal Pain Plus Either Elevated Amylase or Lipase 3 x Upper Limit of Normal…
Phase 3 N=1,950 Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: The Proportion of Subjects in Each Study Group With Post-ERCP Pancreatitis — 145; 110; 137; 90 Participants
N/A N=394 Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Sensitivity and Specificity of Urine Trypsinogen-2 Dipstick Testing for the Diagnosis of Post-ERCP Pancreatitis — 11.1; 91; 4.4; 96.5 percentage of participants
N/A N=117 A Double-blind Study to Determine if Intraduodenal Indomethacin Can Decrease the Incidence of Post-ERCP Pancreatitis
Pancreatitis
Primary: Reduction in Pancreatitis Rate — 16.1; 4.9 percentage of participants with PEP
N/A N=148 SpHincterotomy for Acute Recurrent Pancreatitis
Pancreatitis · Pancreas Divisum · Pancreatitis, Acute
Primary: Reduce the Risk of Subsequent Acute Pancreatitis Episodes by 33% — 32; 26 Participants
Phase 3 N=1,037 Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis
Post-ERCP Pancreatitis
Primary: Number of Participants Who Developed Post-ERCP Pancreatitis — 76; 65 Participants
N/A N=960 Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis
Post-ERCP Acute Pancreatitis
Primary: Number of Patients Who Developed Post-ERCP Pancreatitis — 31; 32 Participants
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
Phase 4 N=1,370 Rectal Indomethacin to Prevent Post ESWL-pancreatitis
Pancreatitis
Primary: the Incidence of Post-ESWL Pancreatitis — 60; 84 Participants
N/A N=151 Study of Forceps Cannulation During ERCP
Post-ERCP Acute Pancreatitis
Primary: Cannulation Success Rate and Difficult Cannulation Rate — 70; 68; 0; 13 Participants
Phase 3 N=170 Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection
Injury of Body of Pancreas
Primary: Number of Participants With Biochemical Leak/Grade B Fistula/Grade C Fistula — 25; 16; 3; 5 Participants
N/A N=399 Pancreas Resection With and Without Drains
Pancreas Tumor · Pancreatitis
Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804
Phase 3 N=168 Closed Suction Drainage and Natural Drainage of the Pancreatic Duct in Pancreaticojejunostomy
Pancreatic Fistula
Primary: Number of Patients With Pancreatic Fistula — 9; 8 participants
Phase 3 N=42 A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis
Acute Pancreatitis
Primary: Systemic Inflammatory Response Syndrome (SIRS) Score — -0.96; -1 score on a scale — p=0.87
Phase 1 N=33 Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms
Neoplasms, Cystic, Mucinous, and Serous
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 7; 16 participants
N/A N=57 MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
Healthy Volunteers
Primary: Total Secreted Fluid Volume as Measured by MR-PFT — 79 mL
N/A N=7 Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy
Pancreatobiliary Disease · Altered Gastric Anatomy
Primary: Papilla or Duct-enterostomy Was Reached — 10 ERCPs
Phase 4 N=192 Rectal Indomethacin vs Intravenous Ketorolac
Post-ERCP Acute Pancreatitis
Primary: Post-ERCP Pancreatitis — 15; 21 Participants
N/A N=1 Stereotactic Radiation to Decrease Pancreatic Secretions
Pancreatic Fistulae
Primary: Decreased Secretions — 1 participants
Phase 3 N=133 Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection
Pancreatic Cancer
Primary: Number of Incidences of Grade 3 or Greater Complications — 0; 0 Number of complications
Phase 2 N=52 Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy
Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma
Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants
Phase 4 N=43 Anti-inflammatory Therapy to Improve Outcomes After TPIAT
Pancreatitis, Chronic; Diabetes; Transplant
Primary: Maximal Acute C-peptide Response to Glucose (ACRmax) — 1.06; 1.52; 1.29 ng/mL*min
Phase 3 N=83 Pentoxifylline Treatment in Acute Pancreatitis (AP)
Acute Pancreatitis (AP) · Gallstone Pancreatitis · Alcoholic Pancreatitis
Primary: Change in C-reactive Protein (C-RP) From Admission Baseline at One Week. — 86.2; 75.8; 116.4; 127.2 mg/L — p=0.5796
N/A N=297 Spy II Clinical Registry
Biliary Tract Diseases
Primary: Procedural Success as Defined by: 1. Ability to Visualize Stricture & Obtain Biopsy of Lesion Adequate for Histological Examination in Suspected Malignancy Cases or 2…
Phase 2 N=12 Secretin Infusion for Pain Due to Chronic Pancreatitis
Chronic Pancreatitis
Primary: VAS Score at Baseline, Days 1, 2, 3, 4, 7, 30. — 5.71; 6.04; 4.92; 4.87 units on a scale — p=.25
Phase 3 N=54 A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and Pancreatectomy
Chronic Pancreatitis · Pancreatectomy · Pancreatic Exocrine Insufficiency
Primary: Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period. — 31.93; 8.72 Percentage — p=<0.0001
N/A N=67 WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures
Chronic Pancreatitis
Primary: Pain Reduction — 12 Participants — p=0.999